---
title: "297 Biotech Venture Capital Firms in the US (Nov 2026): 25 Free"
last_updated: "2026-11-06"
rows: "297"
free_rows: "25"
source: "SEC Form D filings and our own research"
canonical: "https://theinvestordatabase.com/lists/biotech-investors-us/"
---

# 297 biotech venture capital firms in the US

We list 297 biotech venture capital firms in the US as of November 2026: 294 have an SEC filing on file and 3 were checked on the firm's own website or an official register, and the list was last checked on 6 Nov 2026. The cities with the most head offices on this list are San Francisco (27), New York (23) and Boston (19).

- 297 firms
- 166 with a fund filing or dated deal in the last 12 months
- $81M median fund size on file (SEC Form D, 198 firms)
- 1,473 named decision-makers on file

## First 25 of 297 biotech venture capital firms in the US

| Investor | Type | HQ | Stages (our research) | Focus (our research) | Latest fund or deal | Fund size | Checked | Profile |
|---|---|---|---|---|---|---|---|---|
| SR One | VC firm | Wayne, PA |  | Biotech, Healthtech | New fund, Sep 2026 | $600M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/sr-one/ |
| Hatteras Venture Partners | VC firm | Durham, NC | Seed | Biotech, Healthtech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2023) | 2026-11-04 | https://theinvestordatabase.com/investors/hatteras-venture-partners/ |
| First In Ventures | VC firm | Hobe Sound, FL | Pre-seed, Seed | Biotech, Healthtech, AI, Climate Tech | New fund, Sep 2026 | $22M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/first-in-ventures/ |
| AMR Action Fund | VC firm | Boston, MA |  | Biotech, Healthtech, Media, Medtech | Portfolio news, Aug 2026 | $977M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/amr-action-fund/ |
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Biotech, Healthtech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/longitude-venture-partners/ |
| Digitalis Ventures | VC firm | New York, NY | Seed | Biotech, Healthtech, Medtech | Portfolio news, Nov 2026 | $862M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/digitalis-ventures/ |
| Cancer Focus Fund | VC firm | Shreveport, LA |  | Biotech, Healthtech | New fund, May 2026 | $148M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/big-ventures/ |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/madrona/ |
| Gore Range Capital | VC firm | Southlake, TX | Seed | Biotech, Healthtech, Medtech | New deal, Aug 2026 | $250M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/gore-range-capital/ |
| Vida Ventures | VC firm | Los Angeles, CA |  | Biotech, Healthtech | New fund, Sep 2026 | $750M (SEC Form D, 2021) | 2026-11-04 | https://theinvestordatabase.com/investors/vida-ventures/ |
| SOSV | VC firm | United States | Pre-seed | Biotech, Deep Tech, Climate Tech, Healthtech | Portfolio news, Nov 2026 | $131M (SEC Form D, 2022) | 2026-11-04 | https://theinvestordatabase.com/investors/sosv/ |
| ARCH Venture Partners | VC firm | Chicago, IL | Pre-seed, Seed | Biotech, Healthtech, Deep Tech | New fund, Aug 2026 | $3.0B (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/arch-venture-partners/ |
| Narya | VC firm | Columbus, OH | Seed | Biotech, Fintech, Healthtech, Defense Tech | New fund, Sep 2026 | $200M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/narya/ |
| TCGX | VC firm | Palo Alto, CA |  | Biotech, Healthtech | New fund, Oct 2026 | $600M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/tcgx/ |
| Bison Ventures | VC firm | San Francisco, CA | Pre-seed, Seed, Series A, Series B | Biotech, AI, Healthtech, Energy | New fund, Oct 2026 | $160M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/bison-ventures/ |
| NSV | VC firm | Greenwich, CT | Seed, Late stage | Biotech, Healthtech, AI, Semiconductor | Portfolio news, Oct 2026 | $990M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/nsv/ |
| Clarevia | VC firm | Madison, WI |  | Biotech, Healthtech, Medtech | New deal, May 2026 | $100M (SEC Form D, 2023) | 2026-11-05 | https://theinvestordatabase.com/investors/venture/ |
| Mitsui & Co. Global Investment, Inc. | Corporate VC | Menlo Park, CA |  | Biotech, Healthtech, AI, Industrial Tech | Portfolio news, Jun 2026 | $142M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/mitsui-co-global-investment-inc/ |
| Safar Partners | VC firm | Cambridge, MA | Seed | Biotech, Healthtech, Industrial Tech, Deep Tech | New deal, Aug 2026 | $300M (SEC Form D, 2023) | 2026-11-04 | https://theinvestordatabase.com/investors/safar-partners/ |
| Felicis | VC firm | Menlo Park, CA | Seed, Series A | Biotech, AI, Developer Tools, Healthtech | New deal, Oct 2026 | $900M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/felicis/ |
| 8VC | VC firm | Austin, TX |  | Biotech, Data, AI, Healthtech | New deal, Oct 2026 | $400M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/8vc-austin-2/ |
| True Ventures | VC firm | Palo Alto, CA | Pre-seed, Seed | Biotech, AI, Fintech, Deep Tech | New fund, Sep 2026 | $800M (SEC Form D, 2022) | 2026-11-04 | https://theinvestordatabase.com/investors/true-ventures/ |
| HOF Capital | VC firm | New York, NY | Any stage | Biotech, AI, Fintech, Consumer | New fund, Aug 2026 | $300M (SEC Form D, 2021) | 2026-11-04 | https://theinvestordatabase.com/investors/hof-capital/ |
| Battery Ventures | VC firm | Boston, MA | Any stage | Biotech, Energy, Future of Work, Data | Portfolio news, Jul 2026 | $3.2B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/battery-ventures/ |
| Transpose Platform | VC firm | Houston, TX | Pre-seed | Biotech, AI, Generalist | New fund, Sep 2026 | $500M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/transpose-platform/ |

You are seeing 25 of 297. The full list adds 272 more firms and 1,473 named decision-makers.

Get all 297 firms and 1,473 named contacts, $49, one-time: https://theinvestordatabase.com/buy/list/biotech-investors-us
This page: https://theinvestordatabase.com/lists/biotech-investors-us/

## Method and limits
- Source: 294 of the 297 rows carry an SEC filing (Form D or Form ADV). 289 of the 297 have a website we checked; the other 8 rest on the filing or register entry alone. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule: Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. This list holds VC firms, fund managers and corporate venture arms; accelerators and angel networks are in their own lists. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio.
- Order: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (15) and completeness of the public record (10). Regional focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Fill rates: Of 297 rows: stage 214, sector 297, fund size 268, website 289. In the paid file: named decision-makers on 278 rows, firm email on 92, LinkedIn page on 134, check size on 12.

## Questions
### How many biotech venture capital firms in the US are there?
We list 297 as of November 2026. 166 of the 297 have a fund filing or a dated deal in the last 12 months. The cities with the most are San Francisco (27), New York (23) and Boston (19).

### Which biotech venture capital firms in the US raised a new fund in the last 12 months?
108 of the 297 have a fund filing dated in the last 12 months. The most recent on this list are Hyve Ventures (Nov 2026), Future Ventures (Oct 2026) and Draper Associates (Oct 2026).

### What is the typical fund size of biotech venture capital firms in the US?
The median fund size on file for this list is $81M, across the 198 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 99 do not disclose a size there.

### Which stage do most biotech venture capital firms in the US back?
Of the 214 with a stage on file, seed (158), pre-seed (79) and Series A (58). A firm can back more than one stage, and 83 rows have no stage on file yet.

### Where does the data on biotech venture capital firms in the US come from and how often is it updated?
294 of the 297 rows have an SEC filing on file (Form D or Form ADV) and 3 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 6 Nov 2026 at the latest. The whole file is re-verified twice a year.

### Can I download the list of biotech venture capital firms in the US as a spreadsheet?
Yes. The file holds all 297 rows in Excel and CSV, with 1,473 named decision-makers and 92 firm emails, for $49 one-time. 25 rows are free on this page.